|1.||Lawnicka, Hanna: 2 articles (06/2006 - 05/2003)|
|2.||Karasek, Michal: 2 articles (06/2006 - 05/2003)|
|3.||Pawlikowski, Marek: 2 articles (06/2006 - 05/2003)|
|4.||Kunert-Radek, Jolanta: 2 articles (06/2006 - 05/2003)|
|5.||Limonta, P: 2 articles (06/2001 - 03/2001)|
|6.||Motta, M: 2 articles (06/2001 - 03/2001)|
|7.||Moretti, R M: 2 articles (06/2001 - 03/2001)|
|8.||Winczyk, Katarzyna: 1 article (06/2006)|
|9.||Reiter, Russel J: 1 article (12/2004)|
|10.||Leon-Blanco, Mercedes M: 1 article (12/2004)|
|1.||Breast Neoplasms (Breast Cancer)
06/01/2006 - "The aim of present study was to investigate effects of melatonin, the selective ligand for nuclear RZR/ROR receptors - CGP 52608, and methotrexate on growth of murine 16/C breast cancer cells. "
06/01/2006 - "The breast cancer cells were incubated for 2 days in the presence of melatonin, CGP 52608 (at concentrations of 10(-5)M, 10(-7)M, 10(-9)M, 10-(11)M ) and methotrexate (at concentrations of 0.25 and 0.125 microg/ml). "
06/01/2006 - "Growth-inhibitory action of melatonin and thiazolidinedione derivative CGP 52608 on murine 16/C breast cancer cells."
12/08/2004 - "The RNA expression levels of human catalytic subunit (TERT) and the RNA subunit (TR) of telomerase were analysed after treatment with the agonists of the membrane receptor (S 20098) and the nuclear receptor (CGP 52608) for melatonin in the MCF-7 human breast tumor cell line. "
|2.||Pituitary Neoplasms (Pituitary Adenoma)
07/28/2004 - "Oncostatic activity of CGP 52608 at concentrations 1 microM or lower, and cytotoxicity at 5 and 10 microM, are showed in central nervous system cancer cell lines. "
03/01/2001 - "The growth of DU 145 tumors in nude mice was significantly reduced by treatment with CGP 52608. "
07/28/2004 - "Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells."
05/01/2003 - "Both melatonin and CGP 52608 significantly suppressed growth of tumor cells in vitro in both used concentrations. "
09/01/2001 - "Ten days after induction of tumors, the animals were treated with melatonin or CGP 52608. "
|4.||Prostatic Neoplasms (Prostate Cancer)
09/01/2002 - "CGP 52608 also significantly decreased the capacity of prostate cancer cells to migrate towards a chemotactic stimulus (fibronectin), when plated in the upper compartment of a Boyden's chamber. "
06/01/2001 - "These data indicate that, in human androgen-dependent LNCaP prostate cancer cells, the thiazolidinedione derivative CGP 52608 exerts a strong cytostatic activity, by reducing cell proliferation and by affecting cell cycle distribution through the modulation of the expression of cell cycle-related genes. "
03/01/2001 - "To clarify whether RORalpha activation might affect the proliferation of prostate cancer cells also in vivo, nude mice bearing DU 145 tumor xenografts were treated with CGP 52608 at different doses and the growth of the tumors was followed by caliper measurement. "
|5.||Weight Loss (Weight Reduction)
|2.||Cytoplasmic and Nuclear Receptors (Nuclear Receptors)
|7.||Telomerase (Telomerase Reverse Transcriptase)
|8.||RNA (Ribonucleic Acid)
|10.||Blood Glucose (Blood Sugar)
|1.||Heterologous Transplantation (Xenotransplantation)